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Abstract: 
Background: Seizures appear at stroke presentation, during acute phase or as late 
complication of stroke. Thrombolysis has not been investigated as a risk factor despite its 
potential neurotoxic effect. We try to identify risk factors for seizures during acute phase of 
ischemic stroke in a cohort including thrombolysed patients. 
Methods:  We undertook a case-control study at a single stroke center using data from 
Acute STroke Registry and Analyse of Lausanne (ASTRAL). Patients with seizure 
occurring during the first 7 days following stroke were retrospectively identified. Bi- and 
multivariable statistical analyses were applied to compare cases and randomly selected 
controls. 
Results: We identified 28 patients experiencing from seizures in 2327 acute ischemic 
strokes (1.2%). All seizures occurred during the first 72 hours. Cortical involvement, 
thrombolysis with rt-PA, arterial recanalisation, and higher initial NIHSS were statistically 
associated with seizures in univariated analysis. Backward linear regression identified 
cortical involvement (OR 7.53, 95%-CI: 1.6 – 35.2, p<0.01) and thrombolysis (OR 4.6, 
95%-CI: 1.6 – 13.4, p=0.01) as being independently associated with seizure occurrence. 
Overall, three months outcome measured by the modified Rankin Scale (mRS) was 
comparable in both groups. In the subgroup of thrombolysed patients, outcome was 
significantly worse at 3 months in the seizure group with 9/12 (75%) patients with mRS ≥ 
3, compared to 6/18 (33.3%) in the seizure-free group (p=0.03). 
Conclusions: Acute seizures in acute ischemic stroke were relatively infrequent. Cortical 
involvement and thrombolysis with rt-PA are the principal risk factors. Seizures have a 
potential negative influence on clinical outcome in thrombolysed patients. 
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Introduction 
Stroke patients may experience epileptic seizures at stroke presentation, in the acute 
phase (commonly defined as the first 7 days) or as a late complication1. The incidence of 
post-stroke seizures varies between studies: 8.9% of patients suffering from ischemic or 
hemorrhagic stroke developed post-stroke epilepsy after nine months of follow-up2 and 
3.2% after seven years in another survey3. Reported seizure incidence during the acute 
phase of stroke was 6.3% during the first 24 hours in a mixed stroke population4 and 14% 
during the first week after a hemorrhagic event5.  Younger age6, male gender7, cortical 
involvement and a hemorrhagic component have consistently been found to be seizure 
predictors7. Thrombolysis has, to our knowledge, not been investigated as a risk factor for 
early seizures, despite its potential neurotoxic8 and possible epileptogenic9,10 effects in 
animals. 
The aim of our study was to identify risk factors for seizures during the acute phase of 
ischemic stroke in a large consecutive series of patients that included thrombolysed 
patients. 
Methods 
We undertook a case-control study at our tertiary care center. We used data from the 
Acute Stroke Registry and Analyse of Lausanne (ASTRAL)11 containing all acute ischemic 
stroke arriving within 24 hours after last proof of good health at our center. Of note, all 
patients undergo continuous monitoring in our stroke unit for at least 24 hours and for a 
median of 54 hours and are then transferred to a standard hospital bed in the stroke unit. 
Demographics, stroke characteristics, laboratory and imaging data (acute perfusion CT in 
most patients, and subacute head CT or MRI in most patients) and clinical outcome data 
are collected prospectively. Patients whose main diagnosis was transient ischemic attack, 
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primary hemorrhagic stroke and cerebral venous thrombosis were excluded. The scientific 
use of the ASTRAL data was approved by the ethics commission for research on humans 
of the Canton of Vaud, subcommission III.  
In ASTRAL, we retrospectively identified all patients with a seizure according to IALE & 
IBE definition12 during the first 7 days following stroke, including first ever seizures or 
recurrent ones, by searching within the registry and by linking the ASTRAL patients to our 
EEG reports from January 1st 2004 until September 31st 2011 (93 Months). The EEG 
reports are standardized and include the reason for the study, detailed clinical and 
circumstantial description and antiepileptic medications used at the time of the exam.  
As controls, we randomly selected 100 patients from ASTRAL without acute seizures 
during the same time period. Matching was not performed in order to avoid arbitrary 
exclusion of possible precipitating factors. The randomization was done using an EXCEL® 
table, adding an additional variable with the (=RAND) function. Patients were ranked 
according to this new variable. The first hundred patients were selected. 
For each patient, time of seizure’s occurrence, type of seizure according to the ILAE 
classification13, and concomitant anti-epileptic treatment were recorded by reviewing the 
according medical files.  
For case and control patients, all data concerning the stroke were extracted from ASTRAL. 
In particular, presence of previous stroke, statin use, and alcohol abuse were assessed. 
Laboratory data included acute glucose, sodium (Na+) and total cholesterol values. Acute 
stroke localization (involving the cortex or not), etiology according to the TOAST 
classification14 plus dissection, NIHSS on admission, and use of iodine contrast for acute 
imagery were also assessed. Intravenous thrombolysis with recombinant tissue 
plasminogen activator (rt-PA) or acute endovascular treatments according to current 
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guidelines15,16, the presence of arterial occlusion on initial arterial imaging (mostly CT-
angiography), partial or complete recanalisation at 12-48 hour follow-up imaging (CT- or 
MR-angiography or Doppler), and symptomatic hemorrhagic transformation according to 
the ECASS-II trial17, and radiological hemorrhagic transformation according to the ECASS 
classification (when a control imagery was available)  were also recorded. Finally, the 
modified Rankin Scale (mRS) at seven days and three months and mortality were 
obtained either during a follow-up visit at our stroke clinic or by phone by Rankin-certified 
medical personnel. Data not routinely registered in ASTRAL such as previous seizures, 
premorbid and post-stroke use of benzodiazepines and anti-epileptic drugs were obtained 
by reviewing all medical records. 
Comparisons between the two groups were performed using two-tailed Fisher’s exact, χ2, 
Mantel-Haenszel χ2, or t tests, as required. In order to adjust the results for possible 
confounders, the variables which were associated with seizure occurrence with a p < 0.05 
in the univariate analysis were entered in a backward linear regression using acute seizure 
as dependant variable. Receiver operating characteristic (ROC) curves and area under the 
curves (AUC) were calculated for the different regression models. Patients who seized at 
stroke onset were excluded from bi- and multivariate analysis for factors associated with 
seizures’ occurrence. Indeed in those patients, the outcome (seizure) precedes the 
exposition (potential thrombolysis). Analyses were performed with version 9 of the Stata 
software (College Station, TX). 
Results 
We identified 28 patients suffering from acute seizures in 2327 consecutive acute ischemic 
strokes (1.2%). All seizures occurred during the 72 hours of stroke onset and mostly so 
within the first 24 hours (figure 1). Eight (28.5%) patients had seizure at stroke onset. Of 
Alvarez, 6 
 
 
these latter patients, only one received rt-PA (endovascular recanalisation with intra-
arterial use of rt-PA), based on persisting focal deficits and focal hypoperfusion on CT-
perfusion). The seven other patients with seizures at stroke onset were not thrombolysed. 
Most seizures were primarily generalized, followed by focal seizures with impairment of 
consciousness (figure 2). Among the 5 patients with status epilepticus, one had simple 
partial, two had complex partial and two had generalized status epilepticus. Of note, 
seizure’s type distribution was the same in thrombolysed patients and in the non-
thrombolysed ones (table 1). 
Demographics, stroke features, and clinical outcomes are shown in table 2. Demographics 
were globally comparable. Also, there was no difference regarding premorbid treatment or 
for the presence of previous clinical stroke. Moreover, neither prevalence of previous 
seizures nor the premorbid use of anti-epileptic was different in both groups. Symptomatic 
and radiological hemorrhagic transformation occurred in comparable rates in both group. 
The admission metabolic values were also similar. 
Several potential differences emerged in univariate analysis. Cortical involvement was 
significantly associated with seizures (p<0.01), as was thrombolysis with rt-PA (p<0.01). 
Seizure patients had a higher admission NIHSS (p<0.01) and had higher rates of 
recanalisation at follow-up imaging (p<0.01). Regarding stroke etiology, there were no 
global differences, but lacunar infarcts were completely absent in the seizure group. 
Radiological hemorrhagic transformation occurred non-significantly more frequently in the 
control group. Uncertainty regarding the precise time of stroke onset was non significantly 
more frequent in the control group. 
Somewhat more patients in the seizure group tend to reach a poor functional outcome 
(mRS ≥3) at three months (Table 3). However, when analyzing the subgroup of 
thrombolysed patients only (Table 3), outcome was significantly worse at 3 months in the 
Alvarez, 7 
 
 
seizure group, but there was no difference at seven days. Of note, in this subgroup 
analysis, the NIHSS was comparable with a median of 17.5 (+/- 5.7) in seizure group VS 
16.6 (+/- 8.3) in the seizure-free one (p=0.56, t test). The rate of symptomatic hemorrhagic 
transformation was also the same with one patient in each group. 
Backward linear regression including cortical involvement, NIHSS on admission, 
recanalisation thrombolysis identified cortical involvement (OR 7.53, 95%-CI: 1.6 – 35.2, 
p<0.01) and thrombolysis (OR 4.6, 95%-CI: 1.6 – 13.4, p=0.01) as being independently 
associated with seizure occurrence. The ROC curve for the different prediction models are 
shown in the figure 3. Cortical involvement and thrombolysis is shown if figure 3A; the 
AUC is 0.7 (95% CI: 0.55.0-84). The figure 3B shows the ROC curve for cortical 
involvement with an AUC of 0.7 (95% CI: 0.57-0.81) and figure 3C for thrombolysis with a 
AUC of 0.69 (95% CI: 0.55-0.82). 
 
Discussion: 
We found an incidence of 1.2% of seizures within the first 7 days after ischemic stroke, 
which is lower than the previously reported 4.2% of the ischemic subgroup reported by 
Beghi et al. 4, and clearly lower than electrical seizure patterns identified during continuous 
EEG monitoring in such patients reported by our group18.  As opposed to previous studies 
in this field2,3,4,5, we limited our analysis exclusively to ischemic stroke and in acute phase. 
The higher incidence in most previous studies focusing on acute seizure ranging from 
1.2% to 6.3%4,19,20,21,22 may partially be explained by the inclusion of intracerebral 
hemorrhages.  
The other principal finding of our results is the association of acute seizures with 
thrombolysis with rt-PA. Indeed, patients receiving recombinant tissue plasminogen 
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activator (rt-PA) have an OR for seizure occurrence of 4.6 after correction for the main 
confounding factors. This was not explained by symptomatic or radiological hemorrhagic 
transformation as a seizure trigger or sign of reperfusion injury. One hypothetical 
explanation may be recanalisation with free radical production and reperfusion injury that 
may trigger seizures, even in the absence of haemorrhage. A small series23 described 
dramatic neurological recovery after seizures appearing during the thrombolysis with rt-PA. 
The authors argued that the seizures might be a sign of early recanalisation and thus, of a 
good outcome24. However, in our study, recanalization was not associated with seizure 
occurrence in multivariated analysis. 
A further and probably more likely explanation could be related to the rt-PA itself, which is 
known to be neurotoxic in vitro with a large amount of evidence recently reviewed8. 
Moreover, this molecule has also been implicated in epileptogenesis in animal 
model9,25,26. This supports the probable role of rt-PA as of seizure facilitator in acute 
ischemic stroke, and could corroborate the advantage of thrombolytic agents without 
neurotoxic effect27. Moreover it is interesting to note that seizures were not reported as 
side effects in the randomized studies that established the efficacy of rt-PA for ischemic 
stroke28,29,30.  
Toxicity of iodine contrast did not play a role in seizure induction in our cohort: 70% of 
patients with seizure received contrast and 81% did in the control group (p=0.27). 
As previously known, cortical involvement seems to represent the strongest predictor of 
seizure occurrence 2,4, this association also occurs with other brain pathologies such as 
trauma31, and tumor32. In our view this reflect the importance of the neocortex in seizure 
genesis33. 
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Concerning stroke etiology and in contrast to previous studies7,34, our data do not suggest 
that cardiac sources represent an independent relevant factor. However, lacunar infarct 
was completely absent in the seizure group, reinforcing the role of cortical involvement in 
seizure genesis. 
Higher total cholesterol level have been previously described to be “protective” from 
seizure4,19. In this regard, neurosteroids, derived from cholesterol, are known to have an 
anticonvulsant and antiepileptogenic activities35. Moreover, lower cholesterol levels are 
associated with greater risk for symptomatic hemorrhagic transformation after 
recanalisation therapy for ischemic stroke36. Our data do not confirm the “protective” effect 
of hypercholesterolemia or prestroke statin use against acute seizure, perhaps because of 
its marginal effect and limited number of cases. 
As discussed in a comprehensive review1, seizure in the acute stroke setting do probably 
not influence short and long-term outcome when corrected for confounding factors in 
patients without thombolytic treatments. Our study shows a trend to a less favorable 
outcome for patients with seizures; this is possibly explained by the markedly higher 
median NIHSS on admission of these patients (14.8; IQR: 15 vs. 7; IQR: 13, p<0.01) in the 
whole groups. As seizure, in this setting, is a stroke manifestation, it appears logical that 
the outcome is mainly predicted by the brain damage itself.  However in the subgroup 
analysis of thrombolysed patients only, occurrence of seizure is associated with worse 
outcome at 3 month without any difference in NIHSS on admission nor in the symptomatic 
hemorrhagic transformation rate. This finding could have some possible direct 
implications. Indeed as rt-PA is clearly associated with seizures and as their occurrence 
worsen the outcome in the thrombolysed patients, the use of another thrombolytic agent 
could be interesting. 
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Our results show that neither previous seizures, nor the premorbid use of anti-epileptic 
drugs or alcohol abuse has any effect in seizure prediction.  
The limitations of our study are its partially retrospective nature of cases’ identification and 
data collection, which may lead to underascertainment; however, at our center all stroke 
patients with a clinical suspicion of in- or out-of-hospital seizures undergo an EEG, 
including on weekends. Even if the seizure incidence was possibly underestimated, we 
believe that this did not influence the comparison of groups. The relatively low incidence 
may be also explained by our inclusion criteria (only acute setting and after ischemic 
stroke). The relatively low number of patients with seizures limited the power of the study 
to identify other, less important predictors. We also did not analyze the recurrence of 
seizure after the initial 7 days and therefore cannot say whether acute phase seizures 
after ischemic stroke predispose to further seizures later on. Finally, our study shows an 
association between thrombolysis and acute seizures, which do not mean causality. 
In conclusion, acute seizure in ischemic stroke seems relatively infrequent and the cortical 
involvement is the principal risk factor. Our results also show that thrombolysis with rt-PA 
may increase the likelihood of epileptic seizures in the acute phase of ischemic stroke, 
independently from recanalization or symptomatic intracerebral hemorrhage. The outcome 
seems negatively influenced by seizure occurrence in thrombolysed patients only. This 
supports in our view the use of non-epileptogenic thrombolytic agent. In the future, 
seizures in thrombolysed patients should be assessed prospectively in acute but also in 
delayed phase. Indeed, post-stroke epilepsy increases morbidity of stroke. If this 
association is confirmed in chronic phase, “non-epileptogen” thrombolytic agent should be 
even more preferred.  
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Tables & Figures: 
 
Tables: 
 
Table 1: Type of seizure according to acute stroke treatment 
 
 
Thrombolysed patients  
n=12 
Not Thrombolysed patients 
n=16 
P value 
(test) 
n % n % 
0.61 (χ2) 
Focal without 
impairment of 
consciousness 
2 16.7 1 6.3 
Focal with 
impairment of 
consciousness 
3 25 6 37.5 
Generalized 
convulsive 4 33.3 7 43.7 
Status epilepticus 3 25 2 12.5 
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Table 2: Comparison of seizure group (excluding patients with seizure at stroke onset) and 
control group 
 
 
 
Seizure group   
n=20  
Control group  
n=100  p value (test) 
  
n, median 
(IQR) or 
mean (SD) % or range   
n, median 
(IQR) or 
mean (SD) % or range     
 Patients characteristics:               
Age (median and IQR) 0 18-86  70.9 (18.5) 24-93  0.37 (t) 
Male gender 10 50   59 59    0.45 (χ2) 
OH abuse 2 10  7 7  0.92 (Fisher) 
Previous seizures 1 5   4  4   0.99 (Fisher) 
Previous clinical stroke        
Ischemic 6 30   28  28     
Hemorrhagic 0 0  1 1   
None 14 70   71  71   0.89 (Fisher) 
Pre-stroke treatment        
Statin 5 25   24  24   0.92 (χ2) 
Benzodiazepine 2 10  10 10  0.59 (Fisher) 
Anti-epileptic drugs 1 5   4  4   0.99 (Fisher) 
Admission metabolic values  
(mean and SD):        
Glucose value (mmol/l) 6.48 (1.0) 5.1-7.9   7.7a (2.8) 4-19   0.07 (t) 
Na+ (mmol/l) 140 (3.71) 129-145  141 (3.0) 131-140  0.67 (t) 
Cholesterol (mmol/l) 5.1b (1.1) 3.4-7.6   5.51c(1.8) 2.6-15.8   0.31 (t) 
        
Stroke characteristics & treatment:               
Stroke localization               
Involving cortex 18 90  50 50  
<0.01 
(Fisher) 
                
Stroke Etiology        
Atherosclerosis (with ≥50% 
stenosis) 4 20   20 20     
Cardiac 7 35   29  29     
Lacunar 0 0  14 14   
Arterial dissection 1 5   5  5     
Multiple/coexisting 1 5   7  7     
Unknown/rare 7 35  25 25  0.58 (χ2) 
                
Stroke onset        
Known 12 60  53 53   
Approximately known (+/- 1h) 2 10  20 20   
During sleep 3 15  22 22   
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Unknown but <24h 3 15  5 5  0.26 (χ2) 
        
NIHSS on admission (median and 
IQR) 14.8 (15) 1-32  9.35(13) 0-33  <0.01 (t) 
CT with contrast 14 70   81 81    0.26 (χ2) 
Thrombolysis with rt-PA 11 55  18 18  <0.01 (χ2) 
Complete or partial 
recanalisation 
 after documented occlusion 9 45   15  15   <0.01 (χ2) 
Symptomatic hemorrhagic  
transformation  1 5  6 6  0.99 (Fisher) 
        Radiologic hemorrhagic   
transformation when documented 7d 39  10e 19.3  0.094 (χ2)  
a = 99 values/100; b= 17 values/20; c= 90 values/100; d=18 available/20; e=52 available/100 
 
 
 
Table 3: Comparison of clinical outcome of seizure and control group: 
 
ALL PATIENTS:      
 
Seizure group   
n=28  
Control group  
n=100  p value (test) 
Clinical outcome        
mRS ≥3 at 7 days 17 60.7  48 48  0.23 (χ2) 
mRS ≥3 at 3 months 16 57.2   39  39   0.09 (χ2) 
Death at 3 months 6 21.4  18 18  0.68 (χ2) 
        
THROMBOLYSED PATIENTS ONLY:      
 
Seizure group   
n=12  
Control group  
n=18  p value (test) 
Clinical outcome        
mRS ≥3 at 7 days 10 83.3  11 61.1  0.37 (Fisher) 
mRS ≥3 at 3 months 9 75  6 33.3  0.02 (χ2) 
Death at 3 months 2 16.6  4 22.2  0.99 (Fisher) 
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Figures: 
 
Figure 1: Time of seizure occurrence within the first 7 days after acute ischemic stroke 
 
 
 
Figure 2: Type of Seizure according to the ILAE classification13  
 
 
Figure 3: ROC curves for the different variables included in the regression model 
A) For the model including “Cortical involvement” and “thrombolysis”; AUC: 0.7 
(95% CI: 0.55-0.84) 
B) For the variable “Cortical involvement”; AUC: 0.7 (95% CI: 0.59.0-81) 
C) For the variable “Thrombolysis”; AUC: 0.69 (95% CI: 0.55-0.82) 
 
 
 



